Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.47 |
| ▸ | MAP3K5 | Q99683 | 9/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20364350 | 0.94 | TAS2R8 (0.49) | TAS2R8MAP3K5KDM1A | |
| SCHEMBL20364347 | 0.94 | TAS2R8 (0.49) | TAS2R8MAP3K5KDM1AMAPTRECQL | |
| SCHEMBL20367429 | 0.89 | KDM4C (0.44) | TAS2R8MAP3K5HDAC1NAMPTSCD | |
| SCHEMBL20364351 | 0.89 | TAS2R8 (0.42) | TAS2R8MAP3K5HDAC1KDM1AMAPT | |
| SCHEMBL20364348 | 0.85 | MAP3K5 (0.41) | TAS2R8MAP3K5KDM1ACDK5CDK5R1 | |
| SCHEMBL20364363 | 0.85 | ESR2 (0.48) | TAS2R8MAP3K5HDAC1CDK5CDK5R1 | |
| SCHEMBL20170243 | 0.85 | ESR2 (0.47) | TAS2R8MAP3K5CDK5CDK5R1NAMPT | |
| SCHEMBL20364346 | 0.84 | TAS2R8 (0.47) | TAS2R8KDM1AMAPTRECQLCDK5 | |
| SCHEMBL20364334 | 0.83 | MAP3K5 (0.43) | TAS2R8MAP3K5KDM1AMAPTCDK5 | |
| SCHEMBL20367330 | 0.83 | ABCB1 (0.44) | TAS2R8MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | TAS2R8 2479/4885MAP3K5 3026/4885HDAC1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.